Piramal Pharma News, Corporate filings and Earnings/Conference Calls

Name: Latest research reports of Piramal Pharma Ltd. authored by Motilal Oswal and published by - Trendlyne research reports.
Item: Piramal Pharma Ltd.
Rating: 5
Author: Motilal Oswal

Keep track of all breaking news and updates on Piramal Pharma from all sources in a single place.

Piramal Pharma Ltd.

11 Dec 2025

174.45

1.55%

Company Update

Piramal Pharma Ltd - 543635 - Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And …

BSE India

Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015- FDA Inspection

pdf

Piramal Pharma Ltd.

08 Dec 2025

174.45

1.55%

Company Update

Piramal Pharma Ltd - 543635 - Announcement under Regulation 30 (LODR)-Change in Directorate

BSE India

Please find enclosed intimation of appointment of Independent Director.

pdf

Piramal Pharma Ltd.

19 Nov 2025

174.45

1.55%

Company Update

Piramal Pharma Ltd - 543635 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

BSE India

Intimation of Schedule of Analyst/ Institutional Investor Meetings under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

pdf

Piramal Pharma Ltd.

07 Nov 2025

174.45

1.55%

Motilal Oswal Maintains 'Buy' On Piramal Pharma Despite Near-Term Headwinds; Q2 Results Review

NDTV Profit

Motilal Oswal maintains a Buy' rating on Piramal Pharma and revises target price, implying a 20% upside.

Piramal Pharma Ltd. has an average target of 262.67 from 3 brokers.

Piramal Pharma Ltd.

07 Nov 2025

174.45

1.55%

Earnings Call

Piramal Pharma Ltd - 543635 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

BSE India

Please see enclosed Transcript of Conference Call on the Unaudited Financial Results (Standalone & Consolidated) for the quarter ended September 30, 2025

pdf

Piramal Pharma Ltd.

06 Nov 2025

174.45

1.55%

Rebound in US biopharma funding may boost orders, says Piramal Pharma

Business Standard

The drugmaker's revenue fell 9% in Q2FY26 on below-par CDMO performance; company says it faced inconsistent funding in H1FY26

Piramal Pharma Ltd. has an average target of 262.67 from 3 brokers.

Piramal Pharma Q2 performance impacted by CDMO destocking development

Business Line | 06 Nov 2025

Piramal Pharma Ltd.

06 Nov 2025

174.45

1.55%

to see Rapid results content

Piramal Pharma Ltd.

06 Nov 2025

174.45

1.55%

Piramal Pharma Results Earnings Call for Q2FY26

Conference Call with Piramal Pharma Management and Analysts on Q2FY26 Performance and Outlook. Listen to the full earnings transcript.

audio

Piramal Pharma Ltd.

06 Nov 2025

174.45

1.55%

2Q – A miss; higher opex drags earnings

Buy: Piramal Pharma Ltd.

Motilal Oswal

Piramal Pharma (PIRPHARM) delivered in-line revenue for 2QFY62. However, it delivered a miss on EBITDA/PAT for the quarter. Higher operational costs impacted the quarter’s performance.

Piramal Pharma Ltd. has an average target of 262.67 from 3 brokers.

Piramal Pharma Ltd.

05 Nov 2025

174.45

1.55%

Investor Presentation

Piramal Pharma Ltd - 543635 - Announcement under Regulation 30 (LODR)-Investor Presentation

BSE India

Please see enclosed Investor Presentation - Unaudited Financial Results (Standalone & Consolidated) of the Company for the quarter and half year ended September 30, 2025

pdf